IRIS
POGGIO, FRANCESCA BENEDETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.599
AS - Asia 19
SA - Sud America 4
Totale 4.622
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 4.599
CN - Cina 13
SG - Singapore 6
BR - Brasile 4
Totale 4.622
Salva come PNG Salva come JPEG
Città #
Genoa 1.932
Genova 1.853
Rapallo 404
Vado Ligure 388
Bordighera 22
Beijing 9
Singapore 5
Curitiba 1
Sousa 1
São Paulo 1
Votorantim 1
Totale 4.617
Salva come PNG Salva come JPEG
Nome #
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis 193
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 173
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 166
Management of young women with early breast cancer 156
Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of Fc gamma RIIIA/Fc gamma RIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines 152
Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient–level data 143
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: Results of an observational study 143
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis 141
News on the medical treatment of young women with early-stage HER2-negative breast cancer 139
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials 137
New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients 136
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 136
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial 131
Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines 131
The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients 129
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients 127
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients 123
Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study 121
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 121
Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects 119
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study 117
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 117
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial 108
Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do? 106
Role of dose-dense chemotherapy in high-risk early breast cancer 103
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial 103
Patterns of care at the end of life: a retrospective study of Italian patients with advanced breast cancer 102
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival A Randomized Clinical Trial 97
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis 96
Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial 91
Fertility counseling of young breast cancer patients 79
Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis 76
The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancer 73
SNPs of aromatase predict long-term survival and aromatase inhibitor toxicity in patients with early breast cancer: a biomarker analysis of the GIM4 and GIM5 trials 69
"Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper" 65
Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: (ESMO Open (2021) 6(2), (S2059702921000089), (10.1016/j.esmoop.2021.100054)) 55
Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world 54
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial 53
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial 51
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial 50
Choosing the appropriate pharmacotherapy for breast cancer during pregnancy: what needs to be considered? 50
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study 49
Practices and views about palliative care at the end of life: A survey of oncologists from the Italian region of Liguria 47
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 47
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies 42
Different activity and toxicity of immunotherapy in monozygotic twins diagnosed with early triple-negative breast cancer: a case report 38
null 27
Insights on the association of anthropometric and metabolic variables with tumor features and genomic risk in luminal early breast cancer: Results of a multicentric prospective study 25
Totale 4.807
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.521
article - articoli 17.521
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.042
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021256 0 0 0 30 19 38 16 39 17 45 19 33
2021/2022403 15 16 26 50 14 43 10 86 42 39 12 50
2022/2023478 46 51 6 54 71 73 10 38 68 2 57 2
2023/2024287 11 29 4 49 23 21 23 20 15 18 23 51
2024/20251.236 45 74 27 57 134 138 123 250 77 68 125 118
2025/2026825 255 112 305 153 0 0 0 0 0 0 0 0
Totale 4.807